CN Patent

CN110312705B — Gft-505的晶型及其制备方法和用途

Assigned to Crystal Pharmaceutical Suzhou Co Ltd · Expires 2021-07-09 · 5y expired

What this patent protects

涉及GFT‑505的晶型及其制备方法和用途。所提供的GFT‑505的晶型CS1、CS2、CS5和CS6的纯度高，稳定性好，引湿性低，溶解性良好以及机械稳定性高，为含GFT‑505的药物制剂的制备提供了新的更好的选择，对于药物开发具有非常重要的意义。

USPTO Abstract

涉及GFT‑505的晶型及其制备方法和用途。所提供的GFT‑505的晶型CS1、CS2、CS5和CS6的纯度高，稳定性好，引湿性低，溶解性良好以及机械稳定性高，为含GFT‑505的药物制剂的制备提供了新的更好的选择，对于药物开发具有非常重要的意义。

Drugs covered by this patent

Patent Metadata

Patent number
CN110312705B
Jurisdiction
CN
Classification
—
Expires
2021-07-09
Drug substance claim
No
Drug product claim
No
Assignee
Crystal Pharmaceutical Suzhou Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.